Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMVYSLE)

• Drug Name: Cefalotin Drug Info
• Synonyms: Cefalothin; Cefalotina; Cefalotine; Cefalotinum; Cemastin; Cephalothinum; Cephalotin; Coaxin; Cefalotina fabra; Cephalothin Monosodium Salt; Averon-1; Cefalotin (BAN); Cefalotina [INN-Spanish]; Cefalotina fabra (TN); Cefalotine [INN-French]; Cefalotinum [INN-Latin]; Keflin (TN); (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; 3-ACETOXYMETHYL-8-OXO-7-(2-THIOPHEN-2-YL-ACETYLAMINO)-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; 7-(2-Thienylacetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporin; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid
• Therapeutic Class: Antibiotics
• Cross-matching ID:
  PubChem CID: 6024
  ChEBI ID: CHEMBL617
  CAS Number: CAS 153-61-7
  TTD Drug ID: D01PLN
  INTEDE Drug ID: DR2178

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Cortisol synthesis and secretion	-1.73	4.80e-2	58/65 (89.23%)	KCNK2;SP1;GNAS;...
Transcriptional misregulation in cancer	-1.73	4.86e-2	158/192 (82.29%)	CSF2;CEBPA;IL6;...
ErbB signaling pathway	-1.78	2.12e-2	79/85 (92.94%)	CAMK2A;CRKL;NCK2;...
Allograft rejection	-1.79	2.02e-2	32/38 (84.21%)	CD40;CD80;HLA-DQA1;...
Ferroptosis	-1.81	1.88e-2	36/41 (87.8%)	ACSL1;FTL;CP;...
Protein export	-1.96	5.65e-3	17/23 (73.91%)	OXA1L;SRPRA;SEC61A1;...
Asthma	-1.99	7.06e-3	25/31 (80.65%)	CD40;FCER1A;HLA-DQA1;...
Graft-versus-host disease	-2.01	9.41e-3	32/42 (76.19%)	GZMB;IL6;IL1B;...
Antigen processing and presentation	-2.43	0.00e+0	60/78 (76.92%)	CTSS;CD8B;HLA-DQA1;...
Protein processing in endoplasmic reticulum	-2.47	0.00e+0	127/171 (74.27%)	DNAJA2;SEC13;ATF6;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼